CG
ALNY icon

Cutler Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cutler Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,500
Closed -$11K – 3561
2023
Q3 		$11K Buy
+2,500
New +$477K ﹤0.01% 2396
2023
Q1 		– Sell
-600
Closed -$6K – 3708
2022
Q4 		$6K Sell
600
-1,700
-74% -$363K ﹤0.01% 3011
2022
Q3 		$18K Sell
2,300
-13,300
-85% -$2.54M ﹤0.01% 2675
2022
Q2 		$100K Sell
15,600
-2,000
-11% -$284K 0.01% 1444
2022
Q1 		$220K Sell
17,600
-1,600
-8% -$244K 0.01% 1129
2021
Q4 		$58K Buy
+19,200
New +$3.57M ﹤0.01% 2278
2021
Q3 		– Sell
-22,600
Closed -$106K – 5634
2021
Q2 		$106K Buy
+22,600
New +$3.31M ﹤0.01% 1825
2020
Q2 		– Sell
-5,900
Closed -$22K – 4313
2020
Q1 		$22K Sell
5,900
-2,600
-31% -$300K ﹤0.01% 2230
2019
Q4 		$9K Buy
+8,500
New +$847K ﹤0.01% 2682
2019
Q3 		– Sell
-1,500
Closed -$5K – 4002
2019
Q2 		$5K Sell
1,500
-14,500
-91% -$1.11M ﹤0.01% 3047
2019
Q1 		$136K Buy
16,000
+8,700
+119% +$728K 0.01% 833
2018
Q4 		$28K Sell
7,300
-7,100
-49% -$546K ﹤0.01% 1860
2018
Q3 		$65K Buy
14,400
+8,500
+144% +$855K ﹤0.01% 1440
2018
Q2 		$107K Sell
5,900
-6,900
-54% -$684K 0.01% 1111
2018
Q1 		$204K Sell
12,800
-11,200
-47% -$1.44M 0.02% 816
2017
Q4 		$680K Sell
24,000
-153,900
-87% -$19.3M 0.03% 428
2017
Q3 		$4.61M Buy
177,900
+128,300
+259% +$11M 0.17% 84
2017
Q2 		$491K Buy
49,600
+8,800
+22% +$562K 0.02% 703
2017
Q1 		$183K Sell
40,800
-34,700
-46% -$1.6M 0.01% 1262
2016
Q4 		$95K Buy
75,500
+33,400
+79% +$1.4M ﹤0.01% 1950
2016
Q3 		$76K Buy
42,100
+14,300
+51% +$1.01M ﹤0.01% 2043
2016
Q2 		$40K Sell
27,800
-14,600
-34% -$920K ﹤0.01% 2577
2016
Q1 		$120K Buy
42,400
+33,800
+393% +$2.25M 0.01% 1440
2015
Q4 		$15K Buy
+8,600
New +$797K ﹤0.01% 3675

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cutler Group's ALNY Position: Q4 2023 in Review

Cutler Group sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2023, closing a stake of 1,500 shares — an estimated $265K sold.

Cutler Group first reported a position in ALNY in Q4 2015 and held it in 21 quarters. The position peaked at $5.67M in Q4 2017. 498 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

  • Cutler Group reported no remaining Alnylam Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 1,500 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $265K.
  • Cutler Group first reported a position in Alnylam Pharmaceuticals in Q4 2015 and held it in 21 quarters.
  • Cutler Group's Alnylam Pharmaceuticals position peaked at $5.67M in Q4 2017.
  • 498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.